Eli Lilly (LLY): The Drug Companies Never Learn
At least once a year, and probably more often, a big drug company makes a settlement or faces suits over not disclosing the bad effects of one or more of its products. Lilly’s anti-psychotic…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 360Intuitive Surgical Braces For Earnings (ISRG)
Intuitive Surgical Inc. (NASDAQ: ISRG) is set to report earnings after the close on Thursday. Shares closed at $235.00 Wednesday, down from a 52-week high of $359.59 and down from a December 31 close…
Accuray, Neither Recession Proof Nor Credit Proof (ARAY)
Accuray Inc. (NASDAQ: ARAY) is being punished in after-hours trading. The company posted earnings at $0.04 EPS on revenues of $52 million. The problem is that First Call was at $0.09 EPS on $58.2…
Schering-Plough Relief on Partner Earnings (SGP)
Schering-Plough Corp. (NYSE: SGP) is probably breathing a sigh of relief this morning after Merck’s earnings as it is partners with the drug giant on Vytorin and Zetia for cholesterol treatments. The combined Vytorin…
Merck’s Guidance A Relief (MRK)
Merck & Co. (NYSE: MRK) has just posted earnings that may be a relief to many who were worried about recent Vytorin woes affecting 2008 numbers. The company posted EPS of $0.80 for Q4…
The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)
Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis. This data showed that Fampridine, which is designed to treat multiple sclerosis, did not increase…
Amgen’s Earnings & Guidance Make It Almost Look Like A Value Stock
Amgen Inc. (NASDAQ: AMGN) has announced earnings after the company released some positive data this morning. The troubled biotech giant posted $1.00 EPS on a 2% drop in revenues to $3.7 Billion. Amgen estimates…
Amgen Tries Some Positive Data Ahead of Earnings (AMGN)
Amgen Inc. (NASDAQ: AMGN) has announced the results of its biomarker analysis in new data that will be presented on Saturday, January 26th at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. …
Pfizer’s Guidance Holding Up Better Than Skeptics Would Guess (PFE)
Pfizer Inc. (NYSE: PFE) has posted earnings that are lower than last year’s results, but were actually above analyst expectations from First Call. The drug giant posted $0.52 EPS versus $0.47 estimates on $13.1…
Does Martek Hold A Key To Treating Alzheimer’s Disease? (MATK)
Everyone knows about the current and future epidemic of Alzheimer’s Disease. This disease is largely untreated and most current treatments gear around early diagnosis, slowing the onset, or prolonging the early stages from becoming…
Merck (MRK) Losing Out On OTC?
If a company like Merck (MRK) is going to overcome problems with a lot its drugs going "off patent" it is going to have to come up with some new ways to make money.…
Drug Companies Cut Corners Again
Drug companies have put their fingers on the scales to make studies on the "effectiveness of a dozen popular antidepressants" look better than they actually are. According to The Wall Street Journal unpublished data…
The Day In Biotech Stocks (January 15, 2008) (DNA, DNDN, GENZ, TTHI, LCBM, CEGE, GPCB, CGEN)
Today was a brutal day for risk stocks, and biotechs are often thought of as risky to stocks as Russian Roulette is to your head. But Biotechs are also a source of safety IF…
Cramer’s Diagnostics Pick, Pet Blood & Urine… Really (IDXX)
On tonight’s MAD MONEY on CNBC, Jim Cramer came out calling for a move toward being ultra-defensive in what he said is a bear market and fed-mandated recession (here’s our own 2008 defensive stocks…
Will The E.U. Save Dendreon If The U.S. Won’t? (DNDN)
Dendreon Corp. (NASDAQ:DNDN) shares are trading up in early trading on a patent award, and that is after the fairly large gains yesterday. Dendreon was granted a broad European patent covering what is still…